Covalent Modifiers

OCTOBER 21, 2023

Seong Ho Hong , Akane Osa , Ingrid E Wertz , Daniel Nomura bioRxiv 2023.10.20.563371; doi: [link] Targeted protein degradation with Proteolysis Targeting Chimeras (PROTACs) is a powerful therapeutic modality for eliminating disease-causing proteins through targeted ubiquitination and proteasome-mediated degradation.

Targeted Protein Degradation 62

Targeted Protein Degradation Disease 62

Collaborative Drug

OCTOBER 27, 2023

CDD Exhibiting at the 6th Targeted Protein Degradation Summit, Boston, October 31- November 2.

Targeted Protein Degradation 76

Targeted Protein Degradation 76

Covalent Modifiers

MARCH 3, 2023

Calabrese Nat Commun 14 , 1189, 2023 [link] Targeted protein degradation using heterobifunctional chimeras holds the potential to expand target space and grow the druggable proteome. Bridging covalent ligand discovery with chimeric degrader design has emerged as a potential mechanism to advance both fields.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule 52

Sygnature Discovery

MARCH 7, 2023

Sygnature Discovery, the global integrated drug discovery company, has unveiled a new platform that facilitates the combinational high-throughput assembly and review of molecular degraders ( CHARMED ), in response to a sustained rise in demand for its multi-disciplinary expertise. What is the CHARMED platform?

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Drugs 52

Drug Hunter

MAY 21, 2023

This article highlights six recent articles of interest in the field of targeted protein degradation including but not limited to potentially new ligases, recruiting motifs, and a discussion on the feasibility of CNS-penetrant degraders.

Targeted Protein Degradation 131

Targeted Protein Degradation Trials Therapies Disease 131

The Pharma Data

DECEMBER 16, 2020

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

Targeted Protein Degradation 40

Targeted Protein Degradation Bioinformatics Disease Production 40

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Targeted Protein Degradation 130

Targeted Protein Degradation Research Therapies Drugs 130

Practical Cheminformatics

JANUARY 16, 2024

Property Prediction Machine Learning Methods for Small Data Challenges in Molecular Science [link] Practical guidelines for the use of gradient boosting for molecular property prediction [link] Application of message passing neural networks for molecular property prediction [link] Molecular Similarity Molecular Similarity: Theory, Applications, and (..)

Targeted Protein Degradation 141

Targeted Protein Degradation Small Molecule Computational Chemistry Bioinformatics 141

Drug Discovery World

OCTOBER 16, 2023

Professor Henrik Daub , Founder and CSO, NEOsphere Biotechnologies looks at the advancements taking place in proteomics and how targeted protein degradation represents a promising approach for developing new treatments for life-threatening diseases. PROTAC targeted protein degraders: the past is prologue.

Targeted Protein Degradation 147

Targeted Protein Degradation Small Molecule Molecular Biology Treatment 147

Drug Discovery World

FEBRUARY 13, 2024

The study ‘Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127’ elucidates a previously unappreciated oncogenic scaffold function of BTK responsible for clinical resistance to enzymatic inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Treatment Research 130

BioPharma Drive: Drug Pricing

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Targeted Protein Degradation 105

Targeted Protein Degradation Drugs Pharmaceuticals Research 105

Fierce BioTech

MARCH 15, 2024

It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Blue Matter Consulting Resource Type Whitepaper BlueMatterConsulting_250x190 (1) (2).png

Targeted Protein Degradation 52

Targeted Protein Degradation Marketing Therapies Science 52

Drug Hunter

APRIL 23, 2023

BCCov “A covalent BTK ternary complex compatible with targeted protein degradation” Nat.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Trials 130

Drug Discovery World

FEBRUARY 13, 2023

Nello Mainolfi, Founder, President and CEO of Kymera Therapeutics, said: “X-Chem has been a valued partner in helping us to unlock challenging disease targets that can be only or best addressed by targeted protein degradation.

Targeted Protein Degradation 130

Targeted Protein Degradation DNA Disease Drugs 130

Sygnature Discovery

SEPTEMBER 25, 2023

Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Drug Discovery World

NOVEMBER 4, 2022

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration. Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets.

Targeted Protein Degradation 130

Targeted Protein Degradation Engineering Disease Drugs 130

BioPharma Drive: Drug Pricing

SEPTEMBER 7, 2023

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.

Targeted Protein Degradation 68

Targeted Protein Degradation Drugs Research 68

Drug Hunter

JULY 21, 2023

“compound 13” – A DCAF1 binder applied to targeted protein degradation, identified through high-throughput screening and optimization by Novartis.

Structure Based Drug Design (SBDD) 227

Structure Based Drug Design (SBDD) Targeted Protein Degradation Clinical Trials Trials 227

Covalent Modifiers

NOVEMBER 2, 2023

Ashley R Julio, Flowreen Shikwana, Cindy Truong, Nikolas R Burton, Emil Dominguez, Alexandra Turmon, Jian Cao, Keriann Backus bioRxiv 2023.10.30.564067; doi: [link] Protein homeostasis is tightly regulated, with damaged or misfolded proteins quickly eliminated by the proteasome and autophagosome pathways.

Targeted Protein Degradation 64

Targeted Protein Degradation Small Molecule Regulations 64

BMG Labtech

APRIL 16, 2024

Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. 2 Close cousins Both molecular glues and PROteolysis TArgeting Chimeras ( PROTACs ) are targeted-protein degraders.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

Covalent Modifiers

DECEMBER 6, 2023

This approach showcases the potential of nucleophilic amino acid labeling probes, particularly for proteins lacking easily accessible cysteine residues, opening new possibilities for covalent PROTAC design and targeted protein degradation therapies.

Targeted Protein Degradation 62

Targeted Protein Degradation Therapies 62

Covalent Modifiers

FEBRUARY 16, 2024

The qualified inhibitors of SOCS2 could find attractive applications as chemical probes to understand the biology of SOCS2 and its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation.

Targeted Protein Degradation 64

Targeted Protein Degradation Drugs 64

Covalent Modifiers

OCTOBER 19, 2023

The qualified inhibitors of SOCS2 could find attractive applications as chemical probes to understand the biology of SOCS2 and its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation.

Targeted Protein Degradation 73

Targeted Protein Degradation Drugs 73

Broad Institute

FEBRUARY 27, 2024

Past Speakers Speaker Topic Casey Krusemark Encoding chemicals and assays with DNA: Applications in Medicinal Chemistry and Biology Morgan Sheng Schizophrenia and bipolar disorder: from human genetics towards mechanisms and therapeutics Malvina Papanastasiou Structural insights into the LSD1 N-terminus using hydrogen/deuterium exchange-mass spectrometry (..)

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Science 52

Drug Discovery World

JANUARY 15, 2024

VantAI and Blueprint Medicines VantAI and Blueprint Medicines have entered into an amended and restated collaboration and license agreement to design and advance novel targeted protein degrader therapies to address important areas of medical need.

Targeted Protein Degradation 147

Targeted Protein Degradation Small Molecule Drugs Licensing 147

Covalent Modifiers

OCTOBER 3, 2023

3c06622 Targeted protein degradation relies on small molecules that induce new protein–protein interactions between targets and the cellular protein degradation machinery. Chouchani, Mikołaj Słabicki, Eric S. Fischer, Benjamin L. Ebert, Stephen M. Hinshaw, and Nathanael S.

Targeted Protein Degradation 62

Targeted Protein Degradation Small Molecule Drugs 62

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Licensing Licensing 130

Drug Discovery World

MARCH 22, 2023

Oxford Drug Design and PhoreMost advance novel cancer therapeutics Oxford Drug Design has been engaged by PhoreMost to accelerate a targeted protein degradation discovery programme for novel cancer therapeutics.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Drugs Licensing 130

Covalent Modifiers

OCTOBER 10, 2023

Ebert, Nathanael Gray bioRxiv 2023 [link] Small molecules that can induce protein degradation by inducing proximity between a desired target and an E3 ligase have the potential to greatly expand the number of proteins that can be manipulated pharmacologically.

Targeted Protein Degradation 73

Targeted Protein Degradation Small Molecule 73

Zobio

MARCH 8, 2023

In person Molecular glues and targeted protein degraders are changing the landscape of drug discovery. They show great potential for treating diseases such as cancer, infectious, inflammatory, andneurodegenerative diseases, especially for those with “undruggable” pathogenic protein targets.

Targeted Protein Degradation 40

Targeted Protein Degradation Therapies Disease Drugs 40

Zobio

MARCH 8, 2023

In person Molecular glues and targeted protein degraders are changing the landscape of drug discovery. They show great potential for treating diseases such as cancer, infectious, inflammatory, andneurodegenerative diseases, especially for those with “undruggable” pathogenic protein targets.

Targeted Protein Degradation 40

Targeted Protein Degradation Therapies Disease Drugs 40

Covalent Modifiers

FEBRUARY 1, 2024

We therefore set out to understand the nonenzymatic functions of BTK and explored targeted protein degradation to overcome the oncogenic scaffold function of mutant BTK. In this study, we found that a group of these mutants impair BTK kinase activity despite still enabling downstream BCR signaling.

Targeted Protein Degradation 59

Targeted Protein Degradation Clinical Trials Trials Science 59

Drug Discovery World

OCTOBER 6, 2022

Scientific and technological breakthroughs are on the horizon in areas such as targeted protein degradation, cell antigene therapies to customise drugs and monoclonal antibodies being modified in new ways.” . However, the commercialisation of research could improve 8. Volume 23 – Issue 4, Fall 2022. References: .

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

Drug Discovery World

DECEMBER 27, 2023

and seizure liability testing What are the benefits of a target safety assessment?

Targeted Protein Degradation 173

Targeted Protein Degradation Clinical Trials Pharma Companies Drug Development 173

Drug Discovery World

MAY 11, 2023

However, she also presented thoughts in a technical update, Targeted Protein Degradation – Progress, Direction and Prospects. Ubiquigent’s Sheelagh Frame, said: “It was wonderful to share experiences and thoughts about building better workplaces alongside some other inspiring women in life science.”

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. ” About Sosei Heptares.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) International 40

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry. “In

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52